Diazaquinomycin A (1), a new thymidylate (TMP) synthase inhibitor, is poorly soluble in various solvents and exhibits no antitumor activity, while a series of the analogues prepared from 1 are moresoluble in water and chloroform than 1, and some of them exhibit antitumor activity in mice. Someanalogues in which the lactam rings are replaced by pyridine rings did not inhibit TMPsynthase. The diethoxy analogue 25 is a 10-fold more potent inhibitor of TMPsynthase than 1. The diacetoxy analogue 23 exhibits significant antitumor activity (T/C: 175 %) against Meth-A fibrosarcoma in mice.
1 was treated with methyl iodide and silver oxide in chloroform to give the imino ether 2 possessing one 2-methoxypyridine and one lactam ring. Refluxing the reaction mixture afforded 3. Bromination of the two imino ethers gave 4 and 5. Substituting the bromides by a series of nucleophiles such as cyanide, malonate anion, water, acetic acid, ethanol and morpholine, and then hydrolyzing the imino ethers with H2SO4-EtOH gave the diazaquinomycin analogues as shown in Scheme 1. f Present address: Department of Nutrition and Food Science, Ochanomizu University, Otsuka, Bunkyoku, Tokyo 112, Japan. Cyanation of the dibromide 5 with tetraethylammonium cyanide5) gave the dicyanide 6.6) The cyano groups were converted to ethyl esters with H2SO4-EtOHand at the same time the imino ethers were hydrolyzed to give the ester 7. Substitution of 5 by ethyl malonate anion gave the ester 9, and subsequent hydrolysis with H2SO4-EtOH gave the dimalonate ester 10. Successive treatments of 9, such as hydrolysis of the esters with NaOH-aq EtOH, decarboxylation in pyridine and hydrolysis of the imino ethers with H2SO4-EtOH, gave the ester 14. Hydrolysis of the dibromide 5 with water and THFat reflux without acid and base gave the diol 16. The hydroxyl groups were oxidized with CrO3 -H2SO4leading to the dicarboxylic acid 17. Further treatment of 17 with H2SO4-EtOH afforded the ester 18. Hydrolysis with NaOH-aq EtOH gave the corresponding carboxylic acids as shown in Scheme 2. Treatment of the monobromide4 and the dibromide 5 with sodium acetate and acetic acid gave the acetates 20 and 22, which were converted to the monoacetate 21 and the diacetate 23, respectively, with H2SO4 -AcOH.
Alcoholysis of 4 and 5 with H2SO4-EtOH gave the ethyl ethers 24 and 25, respectively, accompanied by hydrolysis of the imino ether. Reaction of 5 with morpholine and a following hydrolysis of the imino ether gave the diamine 27. Table 1 summarizes the antimicrobial activities of the synthesized analogues of 1 against the folate requiring Enterococcus faecium, their reversal by thymidine (TdR), the cytotoxicities against HeLa cells, the inhibitory activities against TMPsynthase prepared from Ehrlich ascites carcinoma cells, and the solubilities in water and chloroform.
Results and Discussion
All mono-or dimethylated analogues of 1 (Types II and III) exhibited extremely reduced biological activities.
The carboxylic acid analogues (8, ll, 15 and 19) were devoid of activities against E. faecium and HeLa cells, but the corresponding esters (7, 10, 14 and 18) were active. Both the carboxylic acids and their esters, however, were more potent inhibitors of TMPsynthase than 1.
These results suggest that the carboxylic acids cannot penetrate the cell membrane.18 exhibited poor activity against E. faecium, but 7 and 14 both containing longer side chains exhibited similar activities against E. faecium as did 1. 7 was most cytotoxic.
Compounds21 and 24, which have substituents on one of the two methyl groups of 1, were only half as potent as 23 and 25, which have the corresponding substituents on both methyl groups of 1. All analogues containing two lactam rings (Type I) were more potent inhibitors of TMPsynthase The results of Lineweaver-Burk plot showed that it inhibits the enzyme competitively with the substrate 5,10-methylene-THF.
With the enzyme, Kmwas 45 /um, and Kiwas 14 fxu. (Fig. 1) . The inhibitory activity of 25 was 10-fold stronger than that of 1. Among the synthesized analogues, three compounds (7, 23 and 25) exhibited activities against
HeLa cells similar to those of 1, and were more soluble in water and chloroform than 1. Their antitumor activities against Meth-A fibrosarcoma in mice were examined and the results are summarized in Table 2 . The diacetoxy derivative 23 exhibited significant antitumor activity (T/C: 175%) corresponding to that of 5-fluorouracil (5-FU).
Experimental MP's were determined on a micro melting point apparatus (Yanaco MP-3). They were uncorrected. NMRspectra were run in CDC13or MeOHW4 on a 90 MHzspectrometer (Jeol FX-90Q). IR spectra were taken on a Jasco A-102 spectrometer. MS were determined by high-resolution , methyl iodide (5 ml, 80.3 mmol) and silver oxide (500 mg, 2.16 mmol) in CHC13 (25 ml) was heated at reflux for 2 hours. As described for 2, the mixture was treated and purified to give a yellow crystalline solid, 235 mg (87%): MP 136~138°C; NMR Table 3 ; IR (CHG13) cm"1 2970, 2880, 1695, 1655; MS calcd for C22H26N2O4, 382.189, observed 382.189.
3-Bromomethyl-2-methoxy-7-methyl-4, 6-dipropylpyrido[3 ,2-gr]quinoline-5 , 8 , 1 0(9^r)-trione (4) j\ solution of 2 (242 mg, 0.66 mmol), iV-bromosuccinimide (242 mg, 1.36 mmol) and benzoyl peroxide (20 mg, 0.08 mmol) in CC14 (93 ml) was heated at reflux for 1 hour. The mixture was cooled at 0°C and filtered. The solids were suspended in CC14 and kept at 50°C for 30 minutes. The suspension was filtered, and the solids were dissolved in CHC13(100 ml). The solution was washed with water (100 ml) and dried over anhydrous Na2SO4. After filtration the solvent was removed to yield a yellow crystalline solid, 224mg (76%): MP 248~250°C; NMR Table 3 ; IR (CHC13) cm"1 3350, 2960, 2925, 1655, 1600; MS calcd for C21H23BrN2O4, 446.084, observed 446.082.
A solution of 3 (500 mg, 1.31 mmol), iV-bromosuccinimide (700 mg, 3.93 mmol) and benzoyl peroxide (10 mg, 0.04 mmol) in CC14 (40 ml) was heated at reflux for 2.5 hours. To the mixture was added water (40 ml) and the product was extracted with CHC13(3 x40 ml). The combined organic extracts were dried (Na2SO4) and evaporated. The resulting crude product was purified by column chromatography, eluting with CHC13. A yellow crystalline solid was obtained 520 mg (74%): MP 226~227°C; NMR A solution of 6 (52 mg, 0.12 mmol) in 30% H2SO4 -EtOH (6 ml) was heated at reflux for 2 hours. To the mixture was added water (5 ml) and the product was extracted with CHC13(3 x5 ml). The combined organic extracts were dried (Na2SO4) and evaporated. The resulting crude product was purified by column chromatography on silica gel, eluting with CHC13 -MeOH(50 : 1 To a suspension of sodium hydride (60% in oil) (388 mg, 16.2mmol) in dry THF (100ml) was added dropwise diethyl malonate (1.8 ml, ll.8 mmol), and the reaction mixture was stirred for 0.5 hour to prepare the anion of diethyl malonate. To the mixture was added a solution of 5 (1.5 g, 2.79 mmol) in dry THF (60 ml), and the resulting solution was stirred for 0.5 hour at room temperature. To the mixture was added EtOH (0.5 ml) to quench the reaction. After concentration in vacuo, water (60 ml) was added to the residue. The mixture was acidified with 1 n HC1, and extracted with CHC13 (3 x60 ml). The combined extracts were dried (Na2SO4) and concentrated in vacuo. The resulting crude product was purified by column chromatography on silica gel, eluting with CHC13. A yellow crystalline solid was obtained, 1.3 g (74%): MP 97~100°C; NMRTable 3; IR (CHC13) cm"1 3010, 1740, 1705, 1675, 1595; MS calcd for C36H46N2O12, 698.305, observed 698.307.
S J-DimethyM^-dipropyW^^J O-tetraoxo -l^^^^J O -hexahydropyridoP^-flrlqumoline -S 'J'-dimalonic Acid Tetraethyl Ester (10)
A solution of 9 (100mg, 0.14mmol) in 30% H2SO4 -EtOH (30ml) was heated at reflux for 12 hours. The mixture was cooled, and concentrated in vacuo. To the mixture was added water (5 ml), and the product was extracted with CHC13. The organic phase was dried (Na2SO4) and concentrated in vacuo. The resulting crude product was purified by column chromatography on silica gel, eluting with CHCl3-MeOH (10:1). A red crystalline solid was obtained, 91 mg (95%): MP 89~92°C; NMR Table 3 ; IR (CHC13) cm"1 3350, 2975, 1725, 1655; MS calcd for C34H42N2O12, 670.274, observed 670.274.
2,8 -Dimethoxy -3,7 -dimethyl -4,6-dipropyldimalonic Acid (12) A mixture of 9 (50 mg, 0.07 mmol) in 80% EtOH -H2O (15 ml) was treated with NaOH (30 mg, 0.75 mmol) and the mixture was heated at reflux for 1 hour. The mixture was acidified with 1 n HC1, and H2O(15 ml) was added. After extracting with CHC13, the organic phase was dried (Na2SO4) and concentrated in vacuo. A yellow crystalline solid was obtained 34 mg (82%): MP300°C; NMR (14) A solution of 13 (34mg, 0.07mmol) in 30% H2SO4-EtOH (15 ml) was heated at reflux for 4 hours. After the reaction was complete according to TLCanalysis, in a similar manner to the preparation of 5, the mixture was treated and purified to give a red crystalline solid, 19 mg (53 %): MP 175~177°C; NMR The mixture was concentrated in vacuo, and water (30 ml) was added. After extracting with CHC13, the organic phase was dried (Na2SO4) and concentrated in vacuo. The resulting crude product was purified by column chromatography on silica gel, eluting with CHC13-MeOH(20 : 1). A yellow crystalline solid was obtained, 27 mg (44%): MP 230~235°C; NMRTable 3; IR (CHC13) cm"1 3400, 2955, 1700, 1670, 1585; MS calcd for C22H26N2O6, 414.179, observed 414.179.
To a solution of 16 (550 mg, 1.33 mmol) in acetone (50 ml) was added a solution of CrO3 -H2SO4 in acetone and the resulting mixture was stirred at 0°C for 10 minutes. To the mixture was added 2-propanol and the mixture was concentrated in vacuo. Further water (150 ml) was added and the product was extracted with CHC13. The organic phase was dried (Na2SO4), and concentrated in vacuo. A yellow crystalline solid was obtained, 510mg (87%): MP231~235°C; NMRTable 3; IR A solution of 17 (210mg, 0.48 mmol) in 30% H2SO4 -EtOH (30ml) was heated at reflux for 5 hours. The mixture was concentrated in vacuo, and water (20 ml) was added. After extracting with CHC13, the organic phase was dried (Na2SO4) and concentrated in vacuo. The resulting crude product was purified by column chromatography on silica gel, eluting with CHC13-MeOH(25 : 1). A red crystalline solid was obtained, 53 mg (50%): MP 230~233°C; NMRTable 3; IR (CHC13) cm"1 3350, 2975, 1735, 1650; MS calcd for C24H26N2O8, 470.169, observed 470.172.
3-Acetoxymethyl-2-methoxy-7-methyl-4,6-dipropylpyrido[3 ,2-gr]quinoline-5 , 8 , 1 0(9ir)-trione (20) To a solution of4 (114 mg, 0.26 mmol) in acetic acid (10 ml) was added NaOH(30 mg, 0.75 mmol) and the resulting mixture was stirred at 100°C for 5 hours. After concentration in vacuo, to the residue was added water (10 ml) and the product was extracted with CHC13. The organic phase was dried (Na2SO4) and concentrated in vacuo. The resulting crude product was purified by column chromatography on silica gel, eluting with CHC13 -MeOH(25 : 1). An orange crystalline solid was obtained, 104mg (96%): MP 188~190°C; NMR 3-Ethoxymethyl-7-methyl-4,6-dipropylpyrido[3 ,2-^]quinoline-2, 5 , 8 , 1 0( l iy,9iJr)-tetrone (24) A solution of 4 (320mg, 0.72mmol) in 30% H2SO4-EtOH (120ml) was heated at reflux for 10 hours. After the reaction was complete according to TLCanalysis, in a similar mannerto the preparation of 5, the mixture was treated and purified to give a red crystalline solid, 100 mg(35 %): 3,7~Diethoxymethyl-4;6-dipropylpyrido [3 ,2^]quinoline-2,5,8, 1 0(l iy,9Jy)-tetrone (25) To a solution of 5 (52mg, 0.09 mmol) in 30% H2SO4-EtOH (8 ml) was heated at reflux for 10 hours. After the reaction was complete according to TLC analysis, in a similar manner to the preparation of 5, the mixture was treated and purified to give a red crystalline solid, 13 mg (32%): MP 233~235°C; NMR mg, 0.09 mmol) in morpholine (2 ml, 22.9 mmol) was stirred for 2 hours at roomtemperature. The mixture was concentrated to dryness in vacuo and to the residue was added 1 n Na2CO3 (10 ml). After extracting with CHC13, the organic phase was dried (Na2SO4) and the solvent removed in vacuo. The resulting crude product was purified by column chromatography on silica gel, eluting with CHC13 -MeOH(40: 1). A yellow crystalline solid was obtained, 33.3 mg (64%): MP 94~95°C; NMR , 0.06mmol) in 30% H2SO4 -EtOH (30ml) was stirred at 100°C for 1.5 hours. After the reaction was complete according to TLCanalysis, in a similar manner to the preparation of 10, the mixture was treated and purified to give a red crystalline solid, 22.1 mg (67%): plemented with 5 % calf serum, benzylpenicillin (lOO u/ml) and streptomycin (100^g/ml) as monolayer culture. Logarithmic phase cells were harvested by treating with trypsin (0.05 %) and EDTA (0.01 %) in calcium and magnesium-free phosphate buffered saline solution. After washing with the growth mediumdescribed above, cells were incubated in wells of 96-well flat bottom microplates (Corning cell wells). Each well contained 0.1 ml of the fresh growth medium supplemented with the compoundsand 5 x103 cells. The compoundswere dissolved in DMSO and added to the medium at the final concentration of 1 %of DMSO. The control well contained DMSO at the same rate. The cells were incubated at 37°C in water-saturated atmosphere of 5 %CO2in air. After incubation for 4 days, the cell growth was observed.
Assay of TMPSynthase The enzymepreparation was obtained according to the method described by Roberts'0 with some modifications. The assay of TMPsynthase from Ehrlich ascites carcinoma was performed as described by Calvert et a/.8) with some modifications described previously.
Antitumor Activity CDFXmice were inoculated ip on day-0 with Meth-A fibrosarcoma (1 x 109 cells/mouse). The tumor had been maintained by ip transfer into BALB/cmice. Beginning 24 hours after tumor cell inoculation, the compounds were administered ip daily for four consecutive days. Antitumor activity was evaluated by the increased life span in the treated groups to that in the control group (T/C).
